Phew! But it is still not (100%) proven that Leron
Post# of 155507
(Total Views: 593)
Posted On: 01/04/2020 7:29:50 AM
Re: Cytodynamite #14250
Quote:
Phew! But it is still not (100%) proven that Leronlimab is going to work for cancer and NASH. But yes, of course, it could.
I must have read over 100 medical papers on just CCR5 and cancer. The action of CCR5 on cancer metastatic and non-metastatic) and what happens when CCR5 is blocked is very well known. I put it at 95% chance of success because there still might be a factor that researchers haven't come across.
With NASh, we know fibrosis is caused by inflammation which CCR5 antagonists highly downregulate. Fat accumulation in the liver is dependent on CCL5, leronlimab blocks that chemokine from the CCR5 receptor. Studies in maraviroc have shown both fibrosis and fat accumulation are lowered.
Looking at the links in trding's Cliff notes should help you understand.
Quote:
Could you give me your personal timeline for targets like $5, $20 or $50+? When do you expect those numbers (based on approvals and so forth)
Share price is going to be entirely dependent on catalysts, those requiring the FDA are out of our control. Much within our control is dependent on getting to revenue. With the number of potential catalysts things could accelerate very quickly.
We'll assume the FDA is not going to do us dirty. If they do then of course the timeline is extended.
All guesses are based somewhat conservatively because I have no idea how many investors are waiting on the sidelines for more proof or how fast we'll gain wider notice.
First thing - BLA filing finalized - I would expect the new floor to be $1.20.
Continuing updates on cancer - a small nudge up in price.
By May we hopefully get some preliminary clinical data in cancer - $1.75
June, very early July FDA approval $2.25 (90 day countdown to Nasdaq listing starts) share price bumps up.
October - Nasdaq listing and increasing script numbers - I would expect $5 from the last week in October to the first week in November.
At that point institutions come in and share price $10 end of year.
After that it will depend on results from other trials and whether we get an early BLA submission in cancer. If we get early BLA we could possibly get approval as early as spring 2021. If no early approval 1Q 2023?
(3)
(0)